Neuroscience-supported research examines whether long-term therapy can slow brain damage after progressive multiple sclerosis.
GLP-1 drugs have been nearly impossible to escape as they dominate weight loss, celebrity culture, diabetes care, and the future of medicine itself. Drugs in this category have been glorified, politicized, overhyped, and, in some corners of the internet, practically mythologized as miracle injections capable of transforming modern health.
However, behind the noise is a question that researchers increasingly cannot ignore: What if these drugs do more than just help people lose weight? This question now reaches neuroscience.
Neurally, Inca wholly owned subsidiary D&D Pharmatechannounced the first patient in an investigator-initiated phase 2 trial evaluating pegsebrenatide (NLY01), the company’s long-acting GLP-1 receptor agonist, for progressive multiple sclerosis (MS) (1). This is a significant moment not only for MS research, but for the broader field of longevity, where scientists are rethinking how inflammation, metabolism, and brain aging are interconnected.
Multiple sclerosis affects more than 2.8 million people worldwide. It is an autoimmune disease in which the body mistakenly attacks myelin, the protective covering of nerve fibers in the brain and spinal cord.
A useful way to think of myelin is as the insulation around electrical wires. When this insulation breaks down, signals between the brain and the body begin to get confused. Over time, this disorder can affect movement, cognition, vision, and speech.
Many current MS treatments focus on calming the immune system and reducing inflammatory attacks. For some patients, these drugs can significantly slow relapses. But progressive MS is different.
Even when the visible inflammation subsides, many patients continue to experience gradual neurological decline as the nerve cells themselves are damaged over time. This process (neurodegeneration) remains one of the most challenging aspects of treating MS. That’s where Neurali believes pegsebrenatide can play a role.
Why researchers are looking at GLP-1 drugs differently
GLP-1 therapies were originally developed for metabolic diseases like diabetes because they help regulate blood sugar and appetite, but scientists have since discovered that GLP-1 receptors are also found in the brain.
The discovery opened a completely new line of research. Additionally, researchers suspect that some GLP-1 drugs may help reduce neuroinflammation, the chronic inflammatory activity that is thought to contribute to diseases such as Parkinson’s, Alzheimer’s, and progressive MS.
The long-term consequences are hard to ignore. Aging itself is now understood as a profound inflammatory process. Some scientists even use the term “inflammation” to describe chronic, low-grade inflammation that accumulates over decades and contributes to age-related diseases.
In this context, the sudden interest in GLP-1 therapy makes more sense. These drugs are not only metabolic drugs; they could eventually become part of a larger toolkit aimed at protecting tissues and maintaining function as people age. The possibility remains speculative, but it is generating a lot of interest across biotechnology.
What makes pegsebrenatide different
Pegsebrenatide is specifically designed as a long-term therapy targeting neurodegenerative disease. In preclinical studies, the drug has shown the ability to suppress neuroinflammation and slow disease progression in animal models of multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease.
Previous clinical data also gave researchers reason to continue progress. In a previous phase 2 Parkinson’s trial involving 255 patients, pegsebrenatide appeared to improve motor symptoms, especially in patients younger than 60 years old.
Importantly, the drug is not developed as a cure. The goal is more nuanced—to slow damage, preserve neurological function, and potentially alter the trajectory of disease progression.
In neurodegenerative medicine, even modest slowing can be significant. For patients, an additional year of mobility, independence, or cognitive stability is no small achievement. This is life changing.
The study, called TAG-MS, is being led by Dr. Ellen Mowry, professor of neurology and epidemiology at Johns Hopkins University, and will be conducted at several academic medical centers.
Approximately 120 patients with progressive MS will participate in the randomized, placebo-controlled study. Participants will receive either pegsebrenatide or a placebo once a week for 96 weeks.
Instead of focusing on the appearance of symptoms, researchers are primarily tracking changes in brain volume through MRI scans. Shrinkage of brain tissue, known as brain atrophy, is considered one of the clearest indicators of ongoing neurodegeneration. The study also examines changes in gray matter, cortical thickness, and disability outcomes.
“We are very excited to advance the clinical development of pegsebrenatide in collaboration with leading MS research centers,” said Seulki Lee, CEO of Neuraly. “Patients with progressive MS face significant unmet medical needs, and neuroinflammation plays a central role in disease progression.”
Lee added that the company sees pegsebrenatide as a “differentiated therapeutic strategy” that targets the underlying inflammatory processes that lead to neurodegeneration.
The biggest story behind the trial
The deeper significance of this trial may not be just about MS. It reflects the broader changes taking place in longevity science itself. For decades, medicine has largely separated metabolic disease, brain disease, and aging into different categories, but biology rarely respects these boundaries.
Chronic inflammation, immune dysfunction, and cellular stress recur in many age-related conditions, from dementia to cardiovascular disease. This has led researchers to a more systems-level understanding of aging.
The GLP-1 boom is perhaps the clearest example of this change. Of course, enthusiasm should be balanced with realism. Neurology is littered with promising treatments that ultimately failed in later-stage trials. The brain remains one of the most challenging frontiers in medicine. However, the fact that researchers are now seriously investigating whether a metabolic drug can help slow neurodegeneration says something important about where the field is headed.
Longevity science is increasingly concerned with preserving function, helping people stay cognitively, physically and socially connected for longer.
